Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Margolin

Showing results (361-370 of 406) with videos related to

Pageof 41
Sort By:
JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaOmid Hamid, Igor Puzanov, Reinhard Dummer, et al.
The Journal of Molecular Diagnostics : JMD|November 6, 2013
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimensColin C Pritchard, Stephen J Salipante, Karen Koehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 17, 2004
A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignanciesS I Shibata, R Pezner, D Chu, et al.
Science Signaling|August 23, 2022
The APP intracellular domain promotes <i>LRRK2</i> expression to enable feed-forward neurodegenerative mechanisms in Parkinson's diseaseZhi-Wei Zhang, Haitao Tu, Mei Jiang, et al.
Nature Biotechnology|June 23, 2014
Assessing the clinical utility of cancer genomic and proteomic data across tumor typesYuan Yuan, Eliezer M Van Allen, Larsson Omberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck CancerChang Xu, Olga Nikolova, Ryan S Basom, et al.
Diseases of the Colon and Rectum|September 28, 2002
A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissuresH Randolph Bailey, David E Beck, Richard P Billingham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 23, 2006
Kidney cancer. Clinical practice guidelines in oncologyRobert J Motzer, Graeme B Bolger, Barry Boston, et al.
Pageof 41

Showing results (361-370 of 406) with videos related to

Sort By:
Pageof 41
JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaOmid Hamid, Igor Puzanov, Reinhard Dummer, et al.
The Journal of Molecular Diagnostics : JMD|November 6, 2013
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimensColin C Pritchard, Stephen J Salipante, Karen Koehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 17, 2004
A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignanciesS I Shibata, R Pezner, D Chu, et al.
Science Signaling|August 23, 2022
The APP intracellular domain promotes <i>LRRK2</i> expression to enable feed-forward neurodegenerative mechanisms in Parkinson's diseaseZhi-Wei Zhang, Haitao Tu, Mei Jiang, et al.
Nature Biotechnology|June 23, 2014
Assessing the clinical utility of cancer genomic and proteomic data across tumor typesYuan Yuan, Eliezer M Van Allen, Larsson Omberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck CancerChang Xu, Olga Nikolova, Ryan S Basom, et al.
Diseases of the Colon and Rectum|September 28, 2002
A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissuresH Randolph Bailey, David E Beck, Richard P Billingham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 23, 2006
Kidney cancer. Clinical practice guidelines in oncologyRobert J Motzer, Graeme B Bolger, Barry Boston, et al.
Pageof 41